Is a hemorrhagic stroke a typical manifestation of Waldenström macroglobulinemia?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 12, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

El evento cerebrovascular hemorrágico NO es una manifestación típica de la macroglobulinemia de Waldenström

El sangrado en la macroglobulinemia de Waldenström (MW) típicamente se manifiesta como epistaxis, sangrado oronasal, hemorragias retinianas o sangrado de mucosas relacionado con hiperviscosidad, no como eventos cerebrovasculares hemorrágicos. 1, 2

Manifestaciones hemorrágicas características de MW

Las complicaciones hemorrágicas en MW ocurren principalmente por:

  • Síndrome de hiperviscosidad: La proteína IgM pentamérica causa viscosidad sérica elevada (>4.0 centipoise), manifestándose como sangrado oronasal y hemorragias retinianas 1, 3
  • Síndrome de von Willebrand adquirido: Defectos en la coagulación por interacción de la IgM con factores de coagulación 4
  • Crioglobulinemia: Presente en hasta 20% de pacientes, sintomática en <5% 3
  • Trombocitopenia: Por infiltración medular 2, 5

Evidencia sobre hemorragia intracerebral

Existe un único reporte de caso de hemorragia intracerebral en MW 6, describiendo un paciente de 65 años con hemorragia intracerebral sin hipertensión asociada y con perfil de coagulación normal. Este caso aislado de 2000 representa una complicación extremadamente rara y atípica.

Caveat clínico importante

Si un paciente con MW presenta un evento cerebrovascular hemorrágico, debe investigarse:

  1. Hiperviscosidad severa (viscosidad sérica >4.0 centipoise) - requiere plasmaféresis urgente 1
  2. Síndrome de von Willebrand adquirido 4
  3. Trombocitopenia severa por infiltración medular
  4. Uso concomitante de inhibidores de BTK (ibrutinib, zanubrutinib) que aumentan riesgo de sangrado 4, 5
  5. Causas no relacionadas a MW (hipertensión, angiopatía amiloide, anticoagulación)

Manejo de hiperviscosidad sintomática

Cuando hay síntomas de hiperviscosidad (incluyendo manifestaciones neurológicas):

  • Plasmaféresis inmediata: 3-4 litros de intercambio plasmático reduce IgM 60-75% y viscosidad ≥50% 1
  • Iniciar terapia citorreductora simultáneamente (régimen DRC o bendamustina-rituximab) 1, 7
  • No esperar resultados de viscosidad sérica para intervenir si hay síntomas clínicos 3

En resumen: La hemorragia intracerebral es una complicación excepcional en MW, no una manifestación característica. Las manifestaciones hemorrágicas típicas son mucocutáneas y retinianas relacionadas con hiperviscosidad.

References

2
Research

Waldenström's macroglobulinemia.

The oncologist, 2000

6
Research

Waldenstrom's macroglobulinaemia with intracerebral haemorrhage.

Journal of postgraduate medicine, 2000

Related Questions

In a patient with Waldenström macroglobulinemia and low IgG who has recurrent urinary tract infections, should pioglitazone (Actos) be continued?
Can you explain Waldenström's macroglobulinemia in simple terms?
How should recurrent shingles be managed in a 67-year-old male with Waldenström macroglobulinemia?
What is the clinical presentation of Waldenström macroglobulinemia?
What are the characteristics of anemia in Waldenström macroglobulinemia compared with anemia in multiple myeloma?
What is the appropriate assessment and management plan for a 62‑year‑old woman presenting with new‑onset atrial fibrillation with rapid ventricular response, intermittent chest pain, dyspnea on exertion, orthopnea, and no prior history of hypertension, diabetes, coronary artery disease, or heart failure?
Is bone removal necessary during meningioma surgery?
In a patient with persistent atrial fibrillation and prior intracardiac sludge who is not a candidate for a Watchman left atrial appendage occlusion device and whose rescheduled electrical cardioversion failed, what is the recommended next-step management regarding anticoagulation, rhythm‑control versus rate‑control strategies, and possible procedural options?
In a patient with atrial fibrillation and left atrial appendage sludge who has been instructed to avoid rate‑control medications until after cardioversion (and not to use them if cardioversion fails), what is the optimal strategy to control the arrhythmia, including anticoagulation and anti‑arrhythmic therapy?
What is the optimal treatment plan for a 39-year-old female with Addison's disease, severe cardiac and gastrointestinal issues in palliative care, and gastroparesis who has cellulitis and an abscess extending from the anal cavity down the left leg past the knee?
What is the appropriate dabigatran (generic) dosing and peri‑procedural management for a patient on dabigatran twice daily undergoing electrical cardioversion, taking renal function into account?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.